Daniel Abdun-Nabi
Director/Board Member chez APTEVO THERAPEUTICS INC.
Fortune : 891 $ au 31/03/2024
Profil
Daniel J.
Abdun-Nabi is currently serving as a Director at Emergent Product Development UK Ltd., Biohealth Innovation, Inc., Aptevo Therapeutics, Inc., and Emergent BioSolutions Canada, Inc. He previously held the position of Chief Executive Officer & Director at Emergent BioSolutions, Inc. from 2018 to 2019.
Additionally, he served as an Independent Director at REGENXBIO, Inc. from 2016 to 2022.
Prior to his current and former roles, Mr. Abdun-Nabi worked as the Secretary, SVP-Legal Affairs & General Counsel at North American Vaccine, Inc. from 1999 to 2000, and as the General Counsel at BioVeris Corp.
and IGEN International, Inc. from 1999 to 2004.
He obtained his undergraduate degree from the University of Massachusetts and his graduate degrees from Georgetown University Law Center and the University of San Diego School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
APTEVO THERAPEUTICS INC
0,03% | 01/03/2024 | 190 ( 0,03% ) | 891 $ | 31/03/2024 |
Postes actifs de Daniel Abdun-Nabi
| Sociétés | Poste | Début |
|---|---|---|
| APTEVO THERAPEUTICS INC. | Director/Board Member | 01/08/2016 |
Biohealth Innovation, Inc.
 Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Director/Board Member | 30/07/2013 |
Emergent BioSolutions Canada, Inc.
 Emergent BioSolutions Canada, Inc. Pharmaceuticals: MajorHealth Technology Emergent BioSolutions Canada, Inc. operates as a biopharmaceutical company that develops and manufactures immune therapeutic drugs. The company is headquartered in Winnipeg, Canada. | Director/Board Member | - |
Emergent Product Development UK Ltd.
 Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Emergent Product Development (UK) Ltd. develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax. It also develops vaccines for meningitis and another for streptococcal infections for infants. The company is a biotechnology company focused on harnessing the immune system to treat and prevent disease in areas of significant unmet clinical needs. It was founded in 1996 and is located in Wokingham, UK. | Director/Board Member | 27/06/2008 |
Anciens postes connus de Daniel Abdun-Nabi
| Sociétés | Poste | Fin |
|---|---|---|
| REGENXBIO INC. | Director/Board Member | 03/06/2022 |
| EMERGENT BIOSOLUTIONS INC. | Chief Executive Officer | 01/04/2019 |
IGEN International, Inc.
 IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | General Counsel | 01/05/2004 |
BioVeris Corp.
 BioVeris Corp. BiotechnologyHealth Technology BioVeris Corp. developed and manufactured diagnostic products. It operates as a global health care and biosecurity company that developing proprietary technologies in diagnostics and vaccinology. The firm specializes in electrochemiluminescence and immunochemistry. The company was founded in 2003 and is headquartered in Gaithersburg, MD. | General Counsel | 01/05/2004 |
North American Vaccine, Inc.
 North American Vaccine, Inc. Pharmaceuticals: OtherHealth Technology North American Vaccine, Inc. develops and sells vaccines for the prevention of infectious diseases. The company is based in Columbia, MD. The company was founded by Jeffrey G. Spragens. North American Vaccine was acquired by Baxter International, Inc. on June 27, 2000 for $250.67 million. | General Counsel | 01/01/2000 |
Formation de Daniel Abdun-Nabi
| University of Massachusetts | Undergraduate Degree |
| Georgetown University Law Center | Graduate Degree |
| University of San Diego School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REGENXBIO INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| APTEVO THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
North American Vaccine, Inc.
North American Vaccine, Inc. Pharmaceuticals: OtherHealth Technology North American Vaccine, Inc. develops and sells vaccines for the prevention of infectious diseases. The company is based in Columbia, MD. The company was founded by Jeffrey G. Spragens. North American Vaccine was acquired by Baxter International, Inc. on June 27, 2000 for $250.67 million. | Health Technology |
BioVeris Corp.
BioVeris Corp. BiotechnologyHealth Technology BioVeris Corp. developed and manufactured diagnostic products. It operates as a global health care and biosecurity company that developing proprietary technologies in diagnostics and vaccinology. The firm specializes in electrochemiluminescence and immunochemistry. The company was founded in 2003 and is headquartered in Gaithersburg, MD. | Health Technology |
IGEN International, Inc.
IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | Health Technology |
Emergent Product Development UK Ltd.
Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Emergent Product Development (UK) Ltd. develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax. It also develops vaccines for meningitis and another for streptococcal infections for infants. The company is a biotechnology company focused on harnessing the immune system to treat and prevent disease in areas of significant unmet clinical needs. It was founded in 1996 and is located in Wokingham, UK. | Health Technology |
Biohealth Innovation, Inc.
Biohealth Innovation, Inc. Financial ConglomeratesFinance Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD. | Finance |
Emergent BioSolutions Canada, Inc.
Emergent BioSolutions Canada, Inc. Pharmaceuticals: MajorHealth Technology Emergent BioSolutions Canada, Inc. operates as a biopharmaceutical company that develops and manufactures immune therapeutic drugs. The company is headquartered in Winnipeg, Canada. | Health Technology |
